Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease entities : Aldeyra therapeutics, inc. save search
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease
Published: 2023-11-27 (Crawled : 23:00) - biospace.com/
ALDX | $3.91 -0.51% -0.51% 450
|
Health Technology
|
| O: -1.19%
H: 5.2%
C: 4.8%
reproxalap drug disease food treatment eye application therapeutics response
DelveInsight Evaluates a Robust Dry Eye Disease Clinical Trial Pipeline as 60+ Influential Pharma Players to Set Foot in the Domain
Published: 2023-05-23 (Crawled : 15:00) - prnewswire.com
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
|
| O: -1.22%
H: 0.0%
C: -0.62%
NVS | News | $97.28 2.27% 1.47% 190K
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: -1.22%
GKOS | $101.1 2.17% 0.0% 350K
|
Health Technology
|
| O: -0.71%
H: 2.06%
C: -1.05%
BHC | $8.53 0.95% 0.0% 500
|
Health Technology
|
| O: -2.27%
H: 4.24%
C: -2.21%
ALC | $80.76 0.19% 0.0% 880K
|
Health Technology
|
| O: -0.51%
H: 0.02%
C: -3.25%
ABBV | News | $169.54 0.98% 0.18% 3.2M
|
Health Technology
|
| O: -0.31%
H: 0.26%
C: -1.34%
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
OCUL | News | $5.0 -1.48% -1.5% 0
|
Health Technology
|
| O: 4.45%
H: 7.65%
C: 2.21%
GRFS | $6.48 2.86% 2.85% 1.5K
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: -3.74%
ALDX | $3.91 -0.51% -0.51% 450
|
Health Technology
|
| O: 0.0%
H: 2.36%
C: 0.61%
pharma disease pipeline set eye trial
Aldeyra Therapeutics Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Disease
Published: 2023-02-28 (Crawled : 14:00) - biospace.com/
ALDX | $3.91 -0.51% -0.51% 450
|
Health Technology
|
| O: 1.26%
H: 3.88%
C: -6.24%
reproxalap disease eye trial therapeutics positive results
Aldeyra Therapeutics Advances Investigational Oral RASP Modulator ADX‑629 Into New Phase 2 Systemic Disease Trials
Published: 2023-02-16 (Crawled : 18:00) - biospace.com/
ALDX | $3.91 -0.51% -0.51% 450
|
Health Technology
|
| O: -1.09%
H: 8.6%
C: 6.62%
trials disease therapeutics phase 2
Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease
Published: 2023-02-07 (Crawled : 13:00) - biospace.com/
ALDX | $3.91 -0.51% -0.51% 450
|
Health Technology
|
| O: 7.27%
H: 4.07%
C: 1.96%
treatment fda drug disease eye application therapeutics reproxalap
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease
Published: 2022-11-29 (Crawled : 14:00) - biospace.com/
ALDX | $3.91 -0.51% -0.51% 450
|
Health Technology
|
| O: -0.38%
H: 6.18%
C: 5.41%
treatment drug disease eye application therapeutics food reproxalap
Aldeyra Therapeutics Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA and Highlights Upcoming Corporate Milestones
Published: 2022-09-14 (Crawled : 14:00) - biospace.com/
ALDX | $3.91 -0.51% -0.51% 450
|
Health Technology
|
| O: 0.0%
H: 1.24%
C: -1.24%
fda disease meeting eye therapeutics positive
Aldeyra Therapeutics Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trial
Published: 2022-07-12 (Crawled : 13:00) - biospace.com/
ALDX | $3.91 -0.51% -0.51% 450
|
Health Technology
|
| O: 1.79%
H: 15.6%
C: 12.97%
disease eye trial therapeutics
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Dry Eye Disease Chamber Crossover Clinical Trial of Reproxalap
Published: 2022-07-11 (Crawled : 22:00) - biospace.com/
ALDX | $3.91 -0.51% -0.51% 450
|
Health Technology
|
| O: 0.22%
H: 2.0%
C: -0.67%
conference disease eye trial therapeutics results topline reproxalap
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 TRANQUILITY‑2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye Disease
Published: 2022-06-08 (Crawled : 13:00) - biospace.com/
ALDX | $3.91 -0.51% -0.51% 450
|
Health Technology
|
| O: 21.45%
H: 0.0%
C: 0.0%
drug disease eye application trial therapeutics phase 3
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease
Published: 2022-06-07 (Crawled : 21:00) - biospace.com/
ALDX | $3.91 -0.51% -0.51% 450
|
Health Technology
|
| O: -1.25%
H: 0.0%
C: 0.0%
conference disease eye trial therapeutics results topline phase 3
Aldeyra Therapeutics Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease
Published: 2022-05-24 (Crawled : 12:00) - biospace.com/
ALDX | $3.91 -0.51% -0.51% 450
|
Health Technology
|
| O: -1.05%
H: 0.0%
C: -4.95%
disease test eye trial therapeutics designation phase 3 reproxalap
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY-2 Trial in Patients with Dry Eye Disease
Published: 2022-04-05 (Crawled : 13:20) - biospace.com/
ALDX | $3.91 -0.51% -0.51% 450
|
Health Technology
|
| O: 0.0%
H: 2.64%
C: -0.82%
disease eye trial therapeutics enroll phase 3
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application (NDA) Submission Guidance
Published: 2021-11-09 (Crawled : 13:15) - biospace.com/
ALDX | $3.91 -0.51% -0.51% 450
|
Health Technology
|
| O: 1.11%
H: 3.41%
C: 1.76%
new drug dry eye disease eye application eye disease drug phase 3 trial submission enroll
Aldeyra Therapeutics Announces Achievement of Primary Endpoint of Ocular Redness in Randomized, Double-Masked, Vehicle-Controlled Phase 2 Clinical Trial in Dry Eye Disease
Published: 2021-11-02 (Crawled : 13:00) - biospace.com/
ALDX | $3.91 -0.51% -0.51% 450
|
Health Technology
|
| O: -0.43%
H: 0.97%
C: -4.65%
dry eye disease phase 2 eye ocular eye disease trial mask
Aldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease
Published: 2021-01-07 (Crawled : 15:00) - biospace.com/
ALDX | $3.91 -0.51% -0.51% 450
|
Health Technology
|
| O: 9.25%
H: 16.67%
C: 15.71%
positive eye disease disease results eye phase 3 trial topline
Aldeyra Announces First Patient Enrolled in the Phase 3 TRANQUILITY Trial of Reproxalap for the Treatment of Dry Eye Disease
Published: 2020-12-08 (Crawled : 19:00) - biospace.com/
ALDX | $3.91 -0.51% -0.51% 450
|
Health Technology
|
| O: 0.56%
H: 3.99%
C: 1.68%
eye disease disease eye phase 3 trial treatment enroll reproxalap
Gainers vs Losers
| 74% | 26% |
Top 10 Gainers
AGBA | $2.97 137.6% 54.87% 66M
|
Finance
RILY | $21.72 0.84% 32.09% 1.9M
|
Finance
HKIT | $1.33 30.39% 27.14% 39K
|
Technology Services
TPET | $0.3601 -4.51% 23.11% 11M
|
n/a
VRT 4 | $79.17 4.08% 19.36% 6.6M
|
Electronic Technology
PEGY | $0.0566 23.58% 15.65% 11M
|
Manufacturing
FOA 4 | $0.5144 -8.16% 15.43% 20
|
Finance and Insurance
BOF | $1.17 6.36% 14.73% 15K
|
LUCY | $0.2545 9.93% 13.94% 66K
|
n/a
TSLA | News | $144.68 1.85% 12.11% 6.9M
|
Consumer Durables
Your saved searches
Save your searches and get alerts when important news are released.